Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 20, 2008

BD to Leverage Accelr8’s BACcel Diagnostic Tool

  • BD intends to fund a research program at Accelr8 until September 30, 2009, under an agreement covering Accelr8’s BACcel™ pathogen diagnostics platform. BD-backed activities at Accelr8 will support BD’s product development in the diagnostics arena.

    BD holds the option to exclusively license Accelr8’s intellectual property in the field of infectious diseases diagnostics. Accelr8 retains commercialization rights for other applications.

    If BD exercises the option during or at the conclusion of the research program, the firm will have to pay an initial fee and running royalties on covered products. Under the license, BD will fund and conduct all product development, manufacturing, and marketing.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »